{
    "nctId": "NCT00476827",
    "briefTitle": "A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain",
    "officialTitle": "A Phase II Safety and Tolerability Study of Avastin When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Safety and Tolerability Will be Assessed According to Standard (CTCAE Version 3.0) Toxicity Reporting Criteria.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, 18+, with evaluable metastatic breast cancer and stable brain metastases\n* Must have received definitive radiotherapy\n* No evidence, or history of, central nervous system hemorrhage\n* Adequate organ and hematological function\n\nExclusion Criteria:\n\n* Active infection, non-healing wound, or history of any bleeding diathesis or coagulopathy\n* Uncontrolled hypertension, congestive heart failure, peripheral vascular disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}